MBX 675Alternative Names: MBX 675 Program; Natural Products Programme - Metabolex
Latest Information Update: 23 Mar 2007
At a glance
- Originator Metabolex
- Class Antihyperglycaemics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 21 Aug 2003 MBX 675 is undergoing optimisation with Metabolex
- 05 Jul 2001 Preclinical development for Type-2 diabetes mellitus in USA (PO)